Stocks · News reference

Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114

Oct 14, 2026, 1:29 PMBenzinga Newsdesk

Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $111 to $114.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Oct 14, 2026, 1:29 PM
Checked: Oct 14, 2026, 1:29 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 9, 2026, 1:09 PMBenzinga Newsdesk
BioMarin Pharmaceutical To Present New Data From Studies Of VOXZOGO In Children With Achondroplasia And Hypochondroplasia And From Studies Of Investigational Long-Acting BMN 333 At American Society For Bone And Mineral Research Meeting; New Analysis Showcases Impact Of VOXZOGO In Foramen Magnum And Craniocervical Junction Growth
BMRN
BenzingaOct 6, 2026, 8:31 PMBenzinga Newsdesk
BioMarin Pharmaceutical Expects Q3 Pre-Tax Charges Of $283M For Bought IPR&d Expense; Expects $1.5 Unfavorable Impact To GAAP And Non-gaap Diluted EPS For Q3; Expects Total Pre-Tax Charges Of $320M For FY26 From Alesta Acquisition; Expects $1.55 Unfavorable Impact To GAAP And Non-Gaap Diluted EPS For FY26
SEC.
BMRN
SEC EDGAROct 6, 2026, 8:22 PMSEC EDGAR
8-K filing — BIOMARIN PHARMACEUTICAL INC (BMRN)
Filed: 2026-10-06 AccNo: 0001048477-26-000019 Size: 148 KB Item 2.02: Results of Operations and Financial Condition
BMRN